Compare Stocks: DFTX, NBIX, JAZZ, and ELAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.10 +2.8%	$38.11	$10.46 ▼ $49.70	$5.12B	2.19	2.24 million shs	1.68 million shs
ELAN Elanco Animal Health	$22.63 -0.1%	$23.16	$19.40 ▼ $27.98	$11.30B	1.7	5.59 million shs	4.39 million shs
JAZZ Jazz Pharmaceuticals	$205.06 -0.8%	$233.50	$128.80 ▼ $266.38	$13.31B	0.37	930,169 shs	816,125 shs
NBIX Neurocrine Biosciences	$145.53 -0.3%	$146.95	$122.14 ▼ $186.12	$14.79B	0.4	1.22 million shs	1.09 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+2.75%	+7.35%	-0.81%	-14.36%	+196.04%
ELAN Elanco Animal Health	-0.15%	+0.45%	+0.79%	-14.55%	+2.26%
JAZZ Jazz Pharmaceuticals	-0.83%	-3.26%	-13.94%	-20.64%	+48.45%
NBIX Neurocrine Biosciences	-0.32%	+2.99%	+3.62%	-21.55%	-1.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.10 +2.8%	$38.11	$10.46 ▼ $49.70	$5.12B	2.19	2.24 million shs	1.68 million shs
ELAN Elanco Animal Health	$22.63 -0.1%	$23.16	$19.40 ▼ $27.98	$11.30B	1.7	5.59 million shs	4.39 million shs
JAZZ Jazz Pharmaceuticals	$205.06 -0.8%	$233.50	$128.80 ▼ $266.38	$13.31B	0.37	930,169 shs	816,125 shs
NBIX Neurocrine Biosciences	$145.53 -0.3%	$146.95	$122.14 ▼ $186.12	$14.79B	0.4	1.22 million shs	1.09 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+2.75%	+7.35%	-0.81%	-14.36%	+196.04%
ELAN Elanco Animal Health	-0.15%	+0.45%	+0.79%	-14.55%	+2.26%
JAZZ Jazz Pharmaceuticals	-0.83%	-3.26%	-13.94%	-20.64%	+48.45%
NBIX Neurocrine Biosciences	-0.32%	+2.99%	+3.62%	-21.55%	-1.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFTX Definium Therapeutics	2.95	Moderate Buy	$66.00	73.23% Upside
ELAN Elanco Animal Health	2.71	Moderate Buy	$29.42	30.01% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$292.05	42.42% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.14	38.21% Upside

Current Analyst Ratings Breakdown

Latest DFTX, NBIX, JAZZ, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	JAZZ Jazz Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$276.00 ➝ $300.00
10/21/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$322.00 ➝ $314.00
10/20/2026	ELAN Elanco Animal Health	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$31.00 ➝ $24.00
10/19/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/16/2026	ELAN Elanco Animal Health	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$32.00
10/16/2026	NBIX Neurocrine Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$204.00
10/15/2026	DFTX Definium Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/12/2026	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$164.00 ➝ $150.00
10/9/2026	DFTX Definium Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$84.00
10/8/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$299.00 ➝ $296.00

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
ELAN Elanco Animal Health	$4.72B	2.40	$2.33 per share	9.70	$13.18 per share	1.72
JAZZ Jazz Pharmaceuticals	$4.60B	2.89	$15.58 per share	13.16	$71.07 per share	2.89
NBIX Neurocrine Biosciences	$3.37B	4.38	$5.11 per share	28.47	$32.63 per share	4.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.68	2.00	-3.96%	8.13%	3.99%	11/6/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	14.14	9.36	0.26	20.45%	33.97%	13.02%	11/2/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	21.34	15.68	0.63	20.91%	22.43%	15.64%	11/2/2026 (Estimated)

Latest DFTX, NBIX, JAZZ, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	ELAN Elanco Animal Health	$0.2028	N/A	N/A	N/A	$1.21 billion	N/A
11/2/2026	Q3 2026	JAZZ Jazz Pharmaceuticals	-$3.81	N/A	N/A	N/A	$1.21 billion	N/A
11/2/2026	Q3 2026	NBIX Neurocrine Biosciences	$1.93	N/A	N/A	N/A	$1.05 billion	N/A
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFTX Definium Therapeutics	0.04	6.95	6.95
ELAN Elanco Animal Health	0.58	2.05	1.10
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFTX Definium Therapeutics	27.91%
ELAN Elanco Animal Health	97.48%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
DFTX Definium Therapeutics	2.40%
ELAN Elanco Animal Health	1.14%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable

DFTX, NBIX, JAZZ, and ELAN Headlines

Recent News About These Companies

Neurocrine Sets Benchmark For Measuring Health Improvements In Tardive Dyskinesia Patients

October 28 at 12:59 PM | rttnews.com

Neurocrine Biosciences, Inc. (NBIX) - What Are Investment Firms Saying About This Stock?

October 27 at 2:30 AM | americanbankingnews.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 27 at 2:28 AM | marketbeat.com

Neurocrine Biosciences, Inc. Presents New Analysis Establishing Benchmark For Clinically Meaningful Change In Overall Health Reported By Patients With Tardive Dyskinesia ...

October 26 at 1:37 PM | marketscreener.comM

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

October 26 at 11:01 AM | zacks.com

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

October 26 at 8:30 AM | prnewswire.com

Neurocrine Biosciences (NASDAQ:NBIX) versus Lyra Therapeutics (OTCMKTS:LYRA) Critical Review

October 26 at 5:15 AM | americanbankingnews.com

Neurocrine Biosciences (NBIX) Set to Announce Quarterly Earnings on Monday

October 26 at 1:40 AM | americanbankingnews.com

Neurocrine Biosciences (NBIX) Projected to Announce Quarterly Earnings on Monday

October 26 at 1:40 AM | marketbeat.com

Where Will Neurocrine Biosciences Be in 5 Years?

October 25, 2026 | fool.com

Where Will Neurocrine Biosciences Be in 5 Years?

October 25, 2026 | fool.com

8,840 Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Diversify Advisory Services LLC

October 25, 2026 | marketbeat.com

Robeco Institutional Asset Management B.V. Acquires 8,833 Shares of Neurocrine Biosciences, Inc. $NBIX

October 24, 2026 | marketbeat.com

Expert Publication On PWS Treatment Could Be A Game Changer For Neurocrine Biosciences (NBIX)

October 24, 2026 | finance.yahoo.com

Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial

October 23, 2026 | finance.yahoo.com

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

October 22, 2026 | prnewswire.com

Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-'567 In Adults With Alzheimer's Disease

October 21, 2026 | marketscreener.comM

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

October 21, 2026 | finanznachrichten.de

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

October 20, 2026 | prnewswire.com

76,788 Neurocrine Biosciences, Inc. $NBIX Shares Sold by Assenagon Asset Management S.A.

October 19, 2026 | marketbeat.com

Needham sets USD 204.00 target for Neurocrine Biosciences stock

October 18, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, NBIX, JAZZ, and ELAN Company Descriptions

Definium Therapeutics NASDAQ:DFTX

$38.10 +1.02 (+2.75%)

As of 10/28/2026 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Elanco Animal Health NYSE:ELAN

$22.63 -0.02 (-0.11%)

Closing price 10/28/2026 03:59 PM Eastern

Extended Trading

$22.93 +0.31 (+1.36%)

As of 07:37 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals NASDAQ:JAZZ

$205.06 -1.72 (-0.83%)

Closing price 10/28/2026 04:00 PM Eastern

Extended Trading

$207.49 +2.43 (+1.19%)

As of 07:55 AM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$145.53 -0.47 (-0.32%)

Closing price 10/28/2026 04:00 PM Eastern

Extended Trading

$146.90 +1.38 (+0.94%)

As of 07:35 AM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DFTX, NBIX, JAZZ, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DFTX, NBIX, JAZZ, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DFTX, NBIX, JAZZ, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, NBIX, JAZZ, and ELAN Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Elanco Animal Health NYSE:ELAN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DFTX, NBIX, JAZZ, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DFTX, NBIX, JAZZ, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DFTX, NBIX, JAZZ, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX, NBIX, JAZZ, and ELAN Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Elanco Animal Health NYSE:ELAN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools